DP
PCVX icon

Diadema Partners’s Vaxcyte PCVX Stock Holding History

Diadema Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.84M Buy
+48,900
New +$2.66M 0.36% 63
2025
Q2 		– Sell
-51,600
Closed -$1.95M – 121
2025
Q1 		$1.95M Buy
+51,600
New +$4.13M 0.51% 45

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Diadema Partners's PCVX Position: Q2 2026 in Review

Diadema Partners increased its Vaxcyte (PCVX) stake by 80% in Q2 2026, buying an estimated $1.09M and bringing the position to 45,071 shares worth $2.62M. The position accounts for 0.33% of the portfolio, ranked #69.

Diadema Partners first reported a position in PCVX in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.86M in Q3 2025. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Diadema Partners held 45,071 shares of Vaxcyte worth $2.62M as of Q2 2026.
  • Diadema Partners bought 20,000 Vaxcyte shares in Q2 2026, an estimated $1.09M.
  • Vaxcyte made up 0.33% of Diadema Partners's portfolio in Q2 2026, its #69 holding.
  • Diadema Partners first reported a position in Vaxcyte in Q4 2024 and has held it in 7 quarters since.
  • Diadema Partners's Vaxcyte position peaked at $7.86M in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.